| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $0 | — | — |
| SG&A Expense | $77K | +368.4% | +313.3% |
| Operating Income | -$77K | -368.4% | -313.3% |
| Interest Expense | $875 | -66.7% | -66.7% |
| Net Income | -$74K | -335.3% | -250.3% |
| EPS (Basic) | $0.00 | — | — |
| EPS (Diluted) | $0.00 | — | — |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Accounts Receivable | $33K | -79.9% | — |
| Current Assets | $15K | -94.1% | — |
| Total Assets | $15K | -94.1% | -93.8% |
| Current Liabilities | $313K | -34.8% | -63.8% |
| Total Liabilities | $313K | -34.8% | -63.8% |
| Stockholders' Equity | -$298K | -33.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$89K | -172.0% | — |
| Investing Cash Flow | -$130K | +0.0% | — |
| Financing Cash Flow | $225K | — | — |
| +51.9% |